Mesika Yossi, Lee Byung Chul, Tsimerman Yevgenia, Roitman Haggai, Park Heon Kyu
IBM Research, Haifa, Israel.
Stud Health Technol Inform. 2011;169:569-73.
Adverse drug event (ADE) has significant implications on patient safety and is recognized as a major cause of fatalities and hospital expenses. Although some medical systems today can help reduce the number of ADE occurrences, these primarily take into account clinical factors-even though recent studies show the significance of genetic profiles in ADE detection. Incorporating pharmacogenetics knowledge and data from genetic test results into these systems can improve the accuracy of preliminary alerts about potential ADEs. However, pharmacogenetics knowledge is unstructured, making it inappropriate for use in a system that involves automatic processing. We propose a methodology that can help incorporate the pharmacogenetics knowledge. Specifically, we show how pharmacogenetics knowledge can be expressed in a medical system and used together with the patient genetic data to provide alerts about ADEs at the point of care.
药物不良事件（ADE）对患者安全具有重大影响，并且被认为是导致死亡和产生医院费用的主要原因。尽管如今一些医疗系统有助于减少ADE的发生数量，但这些系统主要考虑临床因素——即便最近的研究表明基因谱在ADE检测中具有重要意义。将药物遗传学知识和基因检测结果数据纳入这些系统，可以提高对潜在ADE初步警报的准确性。然而，药物遗传学知识是非结构化的，不适用于涉及自动处理的系统。我们提出一种有助于纳入药物遗传学知识的方法。具体而言，我们展示了药物遗传学知识如何在医疗系统中得以表达，并与患者基因数据一起用于在护理点提供有关ADE的警报。
